drugset
drugset / Trial / NCT05267288

Phase II Study of Afatinib Plus Bevacizumab in the Treatment Epidermal Growth Factor Receptor (EGFR) Exon G719X, S768I, and L861Q Mutation Metastatic Non-Small Cell Lung Cancer

NCT05267288 ↗

Phase 2 Unknown 30 enrolled Qingdao Central Hospital
NaSingle-groupOpen-labelTreatment

Summary

There is no report afatinib plus bevacizumab in the treatment of EGFR G719X, S768I, and L861Q single or compond mutation of metastatic non-small-cell lung cancer (NSCLC). The purpose of this study is to study afatinib combined with bevacizumab in the management of it.

Timeline

Start
2021-02-01
Primary completion
2024-12-01
Completion
2025-06-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Afatinib Small molecule 40 mg Oral
Subject Bevacizumab Monoclonal antibody 15 mg/kg Intravenous

Indications

No indication recorded.